Navigation Links
Boston Children's Hospital announces international genomics competition winner
Date:11/7/2012

mutation in all three families, while the University of Iowa team took unique approaches to returning unexpected genetic results based on patient preferences and indicating regions of low coverage or low confidence in their reports.

Answers for families

For one of the three families, CLARITY solved a mystery more than a decade old. Sixth-grader Adam Foye had undergone testing for every gene known to explain his type of muscle weakness, a condition called centronuclear myopathy, always with negative findings. He also has hearing impairment.

Eight of the 23 CLARITY contestants identified alterations in a gene called titin as the cause of Adam's muscle weakness, and six teams identified mutations in a gene called GJB2 as the likely cause of his hearing loss. These results were judged to be correct, and three teams made both identifications.

CLARITY co-organizer Alan Beggs, Ph.D., director of the Manton Center for Orphan Disease Research at Boston Children's, had independently identified titin mutations in four other patients with centronuclear myopathy by using whole-exome sequencing. "Even if we had suspected titin mutations in Adam, it's an enormous gene, and to sequence it individually, by hand, would have taken nine months in the lab, at a prohibitive cost," Beggs says. "That's why genomic sequencing is such a revolutionary technology."

Titin's involvement makes biological sense, Beggs adds, since its protein makes up part of the contractile structure in muscles. Beggs now plans to model the titin defect in zebrafish, allowing his team to do large-scale testing of potential drugs that might correct it.

"We've been celebrating, we've been waiting for an answer for 11 y
'/>"/>

SOURCE Boston Children's Hospital
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
4. Alacrita Establishes U.S. Headquarters in Boston Area
5. BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. Antelope Valley Hospital Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities
8. What Hospitals Must Do to Thrive -- Not Just Survive -- on Medicare Margins
9. Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy
10. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
11. Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... New applications of structures and materials that ... nature over millennia are featured in a special ... in biophotonics in the October issue of the ... by SPIE, the international society for optics and photonics, ... articles are accessible via open access. , “Biomimetic and ...
(Date:10/1/2014)... 2014 Slone Partners , a ... IT, and Laboratory Testing industries, reported a 120% increase ... director level and above from July 2013 to July ... top of rapid breakthroughs in diagnostics, reimbursement has failed ... have been forced to fold, consolidate, or carry on ...
(Date:10/1/2014)... Ill. (PRWEB) October 01, 2014 The ... $9,956,011 to Southern Illinois University Edwardsville as part of ... (TAACCCT) initiative. The funding is co-administered by the Department ... Joe Biden, Secretary of Labor Thomas E. Perez and ... $450 million in job-driven training grants to nearly 270 ...
(Date:10/1/2014)... PHILADELPHIA , October 1, 2014 ... plans to software invited to engage around the theme, ... 29-30     Elsevier ... information products and services, will host a gathering of ... discuss issues and trends impacting healthcare today and in ...
Breaking Biology Technology:Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 2Biomimetic and bioinspired materials enable new healthcare options, reports Journal of Biomedical Optics 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM ... ... 26 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced that the Company ... Monday, March 31,2008, at 5:00 p.m. ET to discuss corporate updates and financial ...
... the Largest Sales Teams Promoting a 5-ASA ... 26 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: ... a co-promotion agreement with,TAP Pharmaceutical Products Inc. ... the induction of remission in patients with,active, ...
... March 26 Thomas W. Burke, MD, Executive ... M.D. Anderson,Cancer Center, has been elected the 40th ... the organization,s 39th Annual Meeting,held March 9-12, 2008 ... undergraduate and medical degrees from Tulane,University in New ...
Cached Biology Technology:Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
(Date:9/30/2014)... that a new class of chemical compounds makes ... have also pinpointed the relevant target enzyme, thus ... , Researchers led by LMU,s Professor Angelika Vollmar ... Mnchen have identified a class of chemicals that ... against malignant tumors. The compound is itself non-toxic, ...
(Date:9/30/2014)... German . ... risky situations such as exposure to predators. Researchers from ... a long-term study on different populations of great tits ... ambient temperature. High metabolic rates and low temperatures were ... birds were more likely to approach potential predators. , ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... In the five months since passage of the ... of research-related awards have been made, supporting important scientific ... increase in basic research funding in American history - ... scientific research and education projects, while $3.5 billion is ...
... 30, 2009) A team of 80 researchers from ... Shifting Sands: Environmental and Cultural Change in Maryland,s Coastal ... barrier islands making up Maryland,s Atlantic coastline. Published ... the history, setting, context and ecology of these waterways, ...
... from the talents of Rembrandt, Van Gogh and other ... of colors on a palette. In a similar manner, ... (NIST) have created an innovative device called the "microfluidic ... concentration across an areain a miniature chamber about the ...
Cached Biology News:'Microfluidic palette' may paint clearer picture of biological processes 2
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
Biology Products: